Meiji Holdings Co Ltd
TSE:2269
Meiji Holdings Co Ltd
Net Income (Common)
Meiji Holdings Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Meiji Holdings Co Ltd
TSE:2269
|
Net Income (Common)
¥49.4B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
|
Yakult Honsha Co Ltd
TSE:2267
|
Net Income (Common)
¥51.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Ajinomoto Co Inc
TSE:2802
|
Net Income (Common)
¥92B
|
CAGR 3-Years
6%
|
CAGR 5-Years
25%
|
CAGR 10-Years
7%
|
|
|
Kikkoman Corp
TSE:2801
|
Net Income (Common)
¥62.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
|
|
Nissin Foods Holdings Co Ltd
TSE:2897
|
Net Income (Common)
¥48.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
19%
|
CAGR 10-Years
9%
|
|
|
Toyo Suisan Kaisha Ltd
TSE:2875
|
Net Income (Common)
¥68B
|
CAGR 3-Years
40%
|
CAGR 5-Years
27%
|
CAGR 10-Years
14%
|
|
Meiji Holdings Co Ltd
Glance View
Meiji Holdings Co., Ltd. has long been a staple in the world of Japanese consumer goods, specifically in the food and pharmaceutical sectors. Established in 2009 as a result of merging Meiji Seika Kaisha, Ltd. and Meiji Dairies Corporation, the company stands as a testament to the power of strategic consolidation, leveraging over a century of expertise from its predecessors. The company's robust product portfolio spans a diverse array of offerings, including dairy products like yogurts and milk, confectioneries like chocolate and candy, as well as nutrition bars and supplements. This triumvirate of product lines allows Meiji Holdings to position itself in both the everyday consumer market and in specialized health-centric industries, exploiting economies of scale and extensive distribution networks that reach far beyond the Japanese archipelago. In the pharmaceutical arena, Meiji Holdings operates under its subsidiary, Meiji Seika Pharma, focusing predominantly on antibacterial drugs, central nervous system treatments, and veterinary products. By integrating research and development with a comprehensive marketing strategy, the company capitalizes on global health trends and regional disease challenges, expanding in markets that emphasize health and dietary improvements. Financially, Meiji Holdings generates revenue by producing goods that tap into both traditional consumer desires and modern nutritional trends. It makes money by introducing high-margin pharmaceutical innovations alongside its well-established consumer brands, thus benefiting from both everyday sales and solutions aimed at pressing global health needs. Together, these strategic components make Meiji Holdings an agile player in a competitive global market, combining heritage with innovation.
See Also
What is Meiji Holdings Co Ltd's Net Income (Common)?
Net Income (Common)
49.4B
JPY
Based on the financial report for Dec 31, 2024, Meiji Holdings Co Ltd's Net Income (Common) amounts to 49.4B JPY.
What is Meiji Holdings Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
5%
Over the last year, the Net Income (Common) growth was -26%. The average annual Net Income (Common) growth rates for Meiji Holdings Co Ltd have been -12% over the past three years , -1% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet